Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
Rhea-AI Summary
Co-Diagnostics (Nasdaq: CODX) announced that its Indian joint venture, CoSara Diagnostics, has initiated clinical studies in India for a tuberculosis (TB/MTB) test on the CoSara PCR Pro point-of-care instrument. According to Co-Diagnostics, PCR Pro instruments, MTB test kits and proprietary sample preparation devices have been shipped and are now deployed in select laboratories across India for TB testing evaluation.
The decentralized platform uses the company’s patented Co-Primers technology to deliver real-time PCR results in about 30 minutes via a mobile app. Co-Dx PCR platform products, including PCR test kits and a sample lysis instrument, are expected to be manufactured and distributed in India under the CoSara brand. India represents a significant share of global TB burden, making it a strategically important market for expanding access to high-quality PCR testing. The Co-Dx PCR platform, including PCR Home, PCR Pro and associated tests, remains subject to regulatory review and is not yet available for sale.
Positive
- CoSara initiates TB test clinical studies on PCR Pro in India
- PCR Pro instruments and MTB test kits deployed to select Indian labs
- Platform delivers real-time PCR TB results in about 30 minutes
- Products expected to be manufactured and distributed in India under CoSara brand
- India’s large TB burden highlights a strategically important target market
Negative
- Co-Dx PCR platform and tests are not yet available for sale
- Platform remains subject to regulatory review/authorization, including potential US FDA clearance
Market reaction after TB clinical study initiation: CODX -3.39% in the Jul 22 session
In the Jul 22 session, CODX declined 3.39%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.4% during that session. Argus tracked a trough of -13.2% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 16 | Leadership appointment | Neutral | -0.2% | Appointed Wes Lindsey as chief scientific officer to support regulatory and commercialization plans. |
| Jul 08 | TB diagnostics workshop | Neutral | -2.6% | Participated in a Bangkok workshop focused on near point-of-care tuberculosis diagnostics. |
| Jul 01 | Clinical study completion | Positive | -0.7% | Completed clinical and analytical studies supporting planned FDA 510(k) submission. |
| Jun 25 | Market expansion | Positive | -14.6% | Expanded Vector Smart mosquito abatement district customer coverage to 21 states. |
| Jun 18 | Joint venture partnership | Positive | -4.8% | Hosted Saudi joint venture partner for an automated PCR test kit manufacturing line unveiling. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
All five selected recent news events were followed by negative 24-hour price reactions, including events described as positive or operationally significant.
Key Terms
mycobacterium tuberculosis medical
real-time pcr technical
point-of-care medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India
The initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform*, following the Company's previously announced shipment of PCR Pro instruments, mycobacterium tuberculosis ("TB" or "MTB") test kits and proprietary sample preparation instruments to CoSara. The decentralized point-of-care platform leverages patented Co-Primers® technology to deliver rapid, gold-standard real-time PCR results in roughly 30 minutes via a mobile application.
The CoSara PCR Pro instrument, the CoSara-branded version of the Co-Dx™ PCR Pro point-of-care instrument, is currently being deployed in select labs across
*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review or authorization by applicable regulatory authorities in the jurisdictions in which clearance or approval is sought, including the US FDA, and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
About CoSara Diagnostics Private Limited:
CoSara Diagnostics Private Limited is an India-based molecular diagnostics company formed as a joint venture between Co-Diagnostics, Inc. and Synbiotics Ltd, a subsidiary of Ambalal Sarabhai Enterprises Ltd. (ASE Group), a continuation of one of the oldest and most respected Indian manufacturing institutions in operation today. CoSara was established in 2017 to manufacture and commercialize molecular diagnostic instruments and assays in India, leveraging Co-Diagnostics' proprietary PCR technology platform while operating under applicable Indian regulatory frameworks. The company is focused on expanding access to high-quality, affordable PCR-based diagnostic solutions for use in India and other permitted markets.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding the conduct, timing, completion and results of clinical studies evaluating the CoSara MTB assay and CoSara PCR Pro instrument; the performance, reliability, speed and potential uses of the Co-Dx PCR platform; the Company's and CoSara's plans regarding regulatory submissions, reviews and authorizations; the potential manufacture, distribution and commercialization of Co-Dx PCR platform products in India and other markets; the anticipated role of distribution and other commercial partners; and the potential for the platform to expand access to PCR-based testing.. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks related to the Company or its joint venture's ability to successfully complete a clinical study for a TB test in India; risks related to the Company' or its joint venture's ability to commercialize the platform in a strategically important market, including risks that distribution partners may not successfully market, promote, or sell the Company's products; risks associated with international operations, including changing regulatory requirements, economic conditions, reimbursement environments, import/export restrictions, and foreign currency fluctuations; risks related to regulatory review by regulatory authorities that would be required to achieve a successful commercial launch; risks related to the performance, reliability, and market acceptance of the Co-Dx PCR platform and other Co-Dx technology; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-initiates-clinical-studies-in-india-for-tuberculosis-test-on-pcr-platform-302831652.html
SOURCE Co-Diagnostics